247 related articles for article (PubMed ID: 31099657)
1. Reassessing the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in 2019.
Psutka SP; Chang SL; Cahn D; Uzzo RG; McGregor BA
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():276-283. PubMed ID: 31099657
[TBL] [Abstract][Full Text] [Related]
2. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.
Bex A; Mulders P; Jewett M; Wagstaff J; van Thienen JV; Blank CU; van Velthoven R; Del Pilar Laguna M; Wood L; van Melick HHE; Aarts MJ; Lattouf JB; Powles T; de Jong Md PhD IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen J
JAMA Oncol; 2019 Feb; 5(2):164-170. PubMed ID: 30543350
[TBL] [Abstract][Full Text] [Related]
4. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
Dahm P; Ergun O; Uhlig A; Bellut L; Risk MC; Lyon JA; Kunath F
Cochrane Database Syst Rev; 2024 Jun; 6(6):CD013773. PubMed ID: 38847285
[TBL] [Abstract][Full Text] [Related]
5. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
6. The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma.
Graham J; Bhindi B; Heng DYC
Curr Opin Urol; 2019 Sep; 29(5):507-512. PubMed ID: 31305275
[TBL] [Abstract][Full Text] [Related]
7. Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma.
Lenis AT; Salmasi AH; Donin NM; Faiena I; Johnson DC; Drakaki A; Gollapudi K; Blumberg J; Belldegrun AS; Pantuck AJ; Chamie K
Urol Oncol; 2018 Feb; 36(2):78.e21-78.e28. PubMed ID: 29128421
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.
Napolitano L; Manfredi C; Cirillo L; Fusco GM; Passaro F; Abate M; La Rocca R; Mastrangelo F; Spirito L; Pandolfo SD; Crocetto F; Arcaniolo D; Barone B
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109725
[TBL] [Abstract][Full Text] [Related]
9. Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.
de Bruijn R; Wimalasingham A; Szabados B; Stewart GD; Welsh SJ; Kuusk T; Blank C; Haanen J; Klatte T; Staehler M; Powles T; Bex A
Eur Urol Oncol; 2020 Apr; 3(2):168-173. PubMed ID: 31956080
[TBL] [Abstract][Full Text] [Related]
10. Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study.
Stroup SP; Raheem OA; Palazzi KL; Liss MA; Mehrazin R; Kopp RP; Patel N; Cohen SA; Park SK; Patterson AL; Kane CJ; Millard F; Derweesh IH
Urology; 2013 Apr; 81(4):805-11. PubMed ID: 23414694
[TBL] [Abstract][Full Text] [Related]
11. Position of cytoreductive nephrectomy in the setting of metastatic renal cell carcinoma patients: does the CARMENA trial lead to a paradigm shift?
Dariane C; Timsit MO; Méjean A
Bull Cancer; 2018 Dec; 105 Suppl 3():S229-S234. PubMed ID: 30595151
[TBL] [Abstract][Full Text] [Related]
12. Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).
De Bruijn RE; Mulders P; Jewett MA; Wagstaff J; Van Thienen JV; Blank CU; Van Velthoven R; Wood L; van Melick HE; Aarts MJ; Lattouf JB; Powles T; De Jong IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen JB; Bex A
Eur Urol; 2019 Oct; 76(4):437-440. PubMed ID: 31227307
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive nephrectomy in metastatic kidney cancer: what do we do now?
Kokorovic A; Rendon RA
Curr Opin Support Palliat Care; 2019 Sep; 13(3):255-261. PubMed ID: 31082942
[TBL] [Abstract][Full Text] [Related]
14. [Symptomatic renal tumours in metastatic renal cell carcinoma - surgical options].
Gilbert N; Merseburger AS; Kramer M
Aktuelle Urol; 2018 Sep; 49(5):417-421. PubMed ID: 30184600
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
16. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.
Massari F; Di Nunno V; Gatto L; Santoni M; Schiavina R; Cosmai L; Brunocilla E; Ardizzoni A; Porta C
Target Oncol; 2018 Dec; 13(6):705-714. PubMed ID: 30324488
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial.
Abu-Ghanem Y; van Thienen JV; Blank C; Aarts MJB; Jewett M; de Jong IJ; Lattouf JB; van Melick HHE; Wood L; Mulders P; Rottey S; Wagstaff J; Zondervan P; Powles T; Neven A; Collette L; Tombal B; Haanen J; Bex A
BJU Int; 2022 Jul; 130(1):68-75. PubMed ID: 34706141
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival.
Patel MI; Beattie K; Bang A; Gurney H; Smith DP
Cancer Med; 2017 Oct; 6(10):2188-2193. PubMed ID: 28834281
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?
Méjean A; Ravaud A; Thezenas S; Chevreau C; Bensalah K; Geoffrois L; Thiery-Vuillemin A; Cormier L; Lang H; Guy L; Gravis G; Rolland F; Linassier C; Lechevallier E; Oudard S; Laguerre B; Gross-Goupil M; Bernhard JC; Colas S; Albiges L; Lebret T; Treluyer JM; Timsit MO; Escudier B
Eur Urol; 2021 Oct; 80(4):417-424. PubMed ID: 34187771
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of immunotherapy-based immediate cytoreductive nephrectomy vs. deferred cytoreductive nephrectomy in metastatic renal cell carcinoma.
Shen XP; Xie M; Wang JS; Guo X
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5684-5691. PubMed ID: 37401306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]